Retinal vein occlusion: drug targets and therapeutic implications

Alessro Arrigo; Francesco Bello

首页> 外文期刊>Expert opinion on therapeutic targets >Retinal vein occlusion: drug targets and therapeutic implications

【24h】

Retinal vein occlusion: drug targets and therapeutic implications

机译：Retinal vein occlusion: drug targets and therapeutic implications

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Introduction: The pathogenesis of retinal vein occlusion (RVO) is extremely complex and includes several mediators. These mediators represent potential drug targets that can be used in the development of intravitreal drugs. Areas covered: PubMed/MEDLINE databases were accessed between April-May 2021 to find the most relevant scientific papers regarding drug targets and therapeutic implications in RVO, focusing on current therapeutic options and potential cornerstones of future advances in treatment. Expert opinion: Before the introduction of intravitreal therapies, the visual outcome following a diagnosis of RVO was extremely poor. Anti-VEGF and corticosteroid treatments have radically changed RVO prognosis, helping to preserve patients’ visual function and their quality of life. According to current clinical data, anti-VEGF and corticosteroid drugs are associated with both pros and cons; the present recommendation is to employ anti-VEGF molecules as a first-line treatment. Advances in our understanding of the biomolecular characteristics of RVO offer a solid basis for the development of new therapeutic targets and treatments.

著录项

来源
《Expert opinion on therapeutic targets》 |2021年第12期|847-864|共18页
作者
Alessro Arrigo; Francesco Bello;
展开▼
作者单位

Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
Retinal vein occlusion; CRVO; BRVO; anti-VEGF; corticosteroids; intravitreal injections; laser;

Retinal vein occlusion: drug targets and therapeutic implications

摘要

著录项

相关主题

期刊订阅